Helius Medical Technologies Inc Class A (HSDT) Stock Forecast
Alert
Its only available to paid users.
USD 24.00
(+369.67%)
Based on the Helius Medical Technologies Inc Class A stock forecast from 1 analysts, the average analyst target price for Helius Medical Technologies Inc Class A is USD 24.00 over the next 12 months. Helius Medical Technologies Inc Class A’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Helius Medical Technologies Inc Class A is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Helius Medical Technologies Inc Class A’s stock price was USD 5.11. Helius Medical Technologies Inc Class A’s stock price has changed by -14.83% over the past week, -12.05% over the past month and -51.56% over the last year.
No recent analyst target price found for Helius Medical Technologies Inc Class A
No recent average analyst rating found for Helius Medical Technologies Inc Class A
Company Overview Helius Medical Technologies Inc Class A
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania. Read Less
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-s...Read More
Frequently Asked Questions About Helius Medical Technologies Inc Class A (HSDT) Stock
Based on ratings from 1 analysts Helius Medical Technologies Inc Class A's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on HSDT's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for HSDT is USD 24.00 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 24.
HSDT stock's Price/Earning ratio is 0.17.
Our analysis grades HSDT stock's Price / Earning ratio at B-. This means that HSDT stock's Price/Earning ratio is above 20% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this HSDT may be undervalued for its sector.
The last closing price of HSDT's stock was USD 5.11.
The most recent market capitalization for HSDT is USD 5.06M.
Based on targets from 1 analysts, the average taret price for HSDT is projected at USD 24.00 over the next 12 months.
This means that HSDT's stock price may go up by +369.67% over the next 12 months.
Following are ETFs with the highest allocation to Helius Medical Technologies Inc Class A's stock :
As per our most recent records Helius Medical Technologies Inc Class A has 26 Employees.
Helius Medical Technologies Inc Class A's registered address is 642 Newtown Yardley Road, Newtown, PA, United States, 18940.
You can get more information about it from Helius Medical Technologies Inc Class A's website at https://heliusmedical.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HSDT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
